Drug news
AzaSite and DexaSite (InSite Vision) enter Phase II for Blepharitis
InSite Vision Inc. commences a 900 patient Phase III trial (DOUBle study)for Azasite Plus ( dexamethasone plus azithromycin)-ISV 502 and DexaSite (dexamethasone)-ISV-305 both using its DuraSite drug delivery platform in the treatment of chronic Blepharitis (or lid margin disease). This condition is an inflammation of the eyelid for which there is no FDA approved treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins